CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients

被引:16
|
作者
Wang, Dan [1 ]
Zhou, Yanhong [2 ]
Hua, Li [2 ]
Li, Jiaxiang [2 ]
Zhu, Ni [2 ]
Liu, Yifei [2 ]
机构
[1] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Pharm, Xianning, Hubei, Peoples R China
[2] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Stomatol & Ophthalmol, Xianning, Hubei, Peoples R China
关键词
colorectal cancer; cyclin-dependent kinases family; mRNA expression; prognosis; risk score model; WEB SERVER; INHIBITORS; EXPRESSION;
D O I
10.2147/IJGM.S349576
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: In the cell cycle, cyclin-dependent kinases (CDKs) play a positive regulatory role, which is essential for normal cell growth, but the expression pattern and prognostic significance of the CDK family in colorectal cancer (CRC) have not been systematically investigated. Methods: In our study, we analyzed and visualized the expression of CDKs in CRC using TCGA, GEPIA, GSCALite, TIMER, HPA database, and R language CDKs risk model was constructed. Results: Overall, CDKs (CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7 and CDK8) were differentially expressed between normal controls and colorectal cancer. Three CDKs genes (CDK3, CDK5 and CDK8) associated with prognosis were obtained by univariate and multivariate Cox and LASSO regression analysis. In CRC, CDK3, CDK5 and CDK8 are significantly associated with expression levels of recognized immune infiltrates. Conclusion: CDK3, CDK5 and CDK8 are potential diagnostic markers for CRC; meanwhile, CDK3, CDK5 and CDK8 are potential prognostic markers for CRC; studying the relationship between CDKs and tumor immunology may be helpful for immunotherapy of CRC, and more studies are needed to confirm these results.
引用
收藏
页码:2233 / 2245
页数:13
相关论文
共 50 条
  • [1] Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer
    Broude, Eugenia V.
    Gyoerffy, Balazs
    Chumanevich, Alexander A.
    Chen, Mengqian
    McDermott, Martina S. J.
    Shtutman, Michael
    Catroppo, James F.
    Roninson, Igor B.
    CURRENT CANCER DRUG TARGETS, 2015, 15 (08) : 739 - 749
  • [2] Inhibition of CDK5 in colorectal cancer
    Robb, Caroline M.
    CANCER RESEARCH, 2015, 75
  • [3] Biological functions of CDK5 and potential CDK5 targeted clinical treatments
    Shupp, Alison
    Casimiro, Mathew C.
    Pestell, Richard G.
    ONCOTARGET, 2017, 8 (10) : 17373 - 17382
  • [4] Phosphoproteomic-based identification of CDK8/CDK19 substrates in colorectal cancer
    Popoola, Olajumoke O.
    Samant, Rahul
    Ortiz-Ruiz, Maria-Jesus
    Mallinger, Aurelie
    Court, Will
    Hobbs, Steve
    Te-Poele, Robert
    Stubbs, Mark
    Burke, Rosemary
    Esdar, Christina
    Schiemann, Kai
    Wienke, Dirk
    Eccles, Sue
    Blagg, Julian
    Workman, Paul
    Clarke, Paul
    CANCER RESEARCH, 2016, 76
  • [5] Role of CDK8 and β-catenin in colorectal adenocarcinoma
    Seo, Jong-Og
    Han, Song Iy
    Lim, Sung-Chul
    ONCOLOGY REPORTS, 2010, 24 (01) : 285 - 291
  • [6] CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
    Ron Firestein
    Adam J. Bass
    So Young Kim
    Ian F. Dunn
    Serena J. Silver
    Isil Guney
    Ellen Freed
    Azra H. Ligon
    Natalie Vena
    Shuji Ogino
    Milan G. Chheda
    Pablo Tamayo
    Stephen Finn
    Yashaswi Shrestha
    Jesse S. Boehm
    Supriya Jain
    Emeric Bojarski
    Craig Mermel
    Jordi Barretina
    Jennifer A. Chan
    Jose Baselga
    Josep Tabernero
    David E. Root
    Charles S. Fuchs
    Massimo Loda
    Ramesh A. Shivdasani
    Matthew Meyerson
    William C. Hahn
    Nature, 2008, 455 : 547 - 551
  • [7] CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
    Firestein, Ron
    Bass, Adam J.
    Kim, So Young
    Dunn, Ian F.
    Silver, Serena J.
    Guney, Isil
    Freed, Ellen
    Ligon, Azra H.
    Vena, Natalie
    Ogino, Shuji
    Chheda, Milan G.
    Tamayo, Pablo
    Finn, Stephen
    Shrestha, Yashaswi
    Boehm, Jesse S.
    Jain, Supriya
    Bojarski, Emeric
    Mermel, Craig
    Barretina, Jordi
    Chan, Jennifer A.
    Baselga, Jose
    Tabernero, Josep
    Root, David E.
    Fuchs, Charles S.
    Loda, Massimo
    Shivdasani, Ramesh A.
    Meyerson, Matthew
    Hahn, William C.
    NATURE, 2008, 455 (7212) : 547 - U60
  • [8] Development of Selective CDK8 Inhibitors for Colorectal Cancer Treatment
    Brzozka, K.
    Zarebski, A.
    Windak, R.
    Krawczynska, K.
    Klosowska, A.
    Dreas, A.
    Fogt, J.
    Cholody, M.
    Milik, M.
    Rzymski, T.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 159 - 160
  • [9] Discovery of CDK signature and CDK5 as potential biomarkers for predicting prognosis and immunotherapeutic response in gastric cancer peritoneal metastases
    Sun, Yuqin
    Chen, Yueqing
    Cai, Yichen
    Wang, Xiangyu
    Chen, Qiuxian
    Fang, Shunyong
    Lian, Mingqiao
    Lv, Chenbin
    Weng, Jianming
    Huang, Rongjie
    Zhuang, Wei
    Xue, Fangqin
    Cai, Lisheng
    Lin, Yao
    Wang, Qingshui
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (09): : 4087 - 4100
  • [10] Biomarkers of Cdk5 driven neuroendocrine tumors
    Carter, Angela M.
    Telange, Rahul
    Oltmann, Sarah
    Nwariaku, Fiemu
    Robinson, Bruce
    Grubbs, Elizabeth
    Bibb, James
    MOLECULAR CANCER RESEARCH, 2016, 14